dual glp 1 and gip receptor agonist GIP/GLP-1 agonists: New advances for treating type-2 diabetes GLP-1 and GIP receptors signal

Secondary outcomes were each of these events considered separately

Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

GLP-1 and GIP receptor agonists are groundbreaking treatments originally developed for diabetes, now also employed in managing obesity

Medicare is already spending billions on drugs like Ozempic, and Biden recently proposed expanding access to obesity treatments.